Lee Dobson

Lee Dobson

Auto-generated profile, based on publicly available information

Lee Dobson

Respiratory Medicine, Royal Devon and Exeter NHS Foundation Trust, Exeter, GBR

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2004 in Diabetic Medicine
Verified
Journal Article
Closed access
PDF file
LDL. Dobson
L. Dobson
CSC. D. Sheldon
C. D. Sheldon
AHA. T. Hattersley
A. T. Hattersley

1 November 2002 in Archives of Disease in Childhood
Verified
Journal Article
Open access
PDF file
LDL Dobson
L Dobson
AHA T Hattersley
A T Hattersley
STS Tiley
S Tiley
SES Elworthy
S Elworthy
POP J Oades
P J Oades
CSC D Sheldon
C D Sheldon

1 August 2015 in Nitric Oxide
Verified
Journal Article
Open access
ASAnthony I. Shepherd
Anthony I. Shepherd
DWDaryl P. Wilkerson
Daryl P. Wilkerson
LDLee Dobson
Lee Dobson
JKJames Kelly
James Kelly
Paul G WinyardPaul G Winyard
Paul G Winyard
MGMark Gilchrist
Mark Gilchrist
Chronic obstructive pulmonary disease (COPD) results in exercise intolerance. Dietary nitrate supplementation has been shown to lower blood pressure (BP), reduce the oxygen cost of exercise, and enhance exercise tolerance in healthy volunteers. This study assessed the effects of dietary nitrate on the oxygen cost of cycling, walking performance and BP in individuals with mild-moderate COPD. Thirteen patients with mild-moderate COPD were recruited. Participants consumed 70 ml of either nitrate-rich (6.77 mmol nitrate; beetroot juice) or nitrate-depleted beetroot juice (0.002 mmol nitrate; placebo) twice a day for 2.5 days, with the final supplement ~3 hours before testing. BP was measured before completing two bouts of moderate-intensity cycling, where pulmonary gas exchange was measured throughout. The six-minute walk test (6 MWT) was completed 30 minutes subsequent to the second cycling bout. Plasma nitrate concentration was significantly elevated following beetroot juice vs. placebo (placebo; 48 ± 86 vs. beetroot juice; 215 ± 84 µM, P = 0.002). No significant differences were observed between placebo vs. beetroot juice for oxygen cost of exercise (933 ± 323 vs. 939 ± 302 ml: min(-1); P = 0.88), distance covered in the 6 MWT (456 ± 86 vs. 449 ± 79 m; P = 0.37), systolic BP (123 ± 14 vs. 123 ± 14 mmHg; P = 0.91), or diastolic BP (77 ± 9 vs. 79 ± 9 mmHg; P = 0.27). Despite a large rise in plasma nitrate concentration, two days of nitrate supplementation did not reduce the oxygen cost of moderate intensity cycling, increase distance covered in the 6 MWT, or lower BP.

1 June 2003 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
LDLee Dobson
Lee Dobson
CSChristopher D. Sheldon
Christopher D. Sheldon
AHAndrew T. Hattersley
Andrew T. Hattersley

1 February 2005 in Pediatric Pulmonology
Verified
Journal Article
Closed access
PDF file
LDL. Dobson
L. Dobson
ASA. Stride
A. Stride
CBC. Bingham
C. Bingham
SES. Elworthy
S. Elworthy
CSC.D. Sheldon
C.D. Sheldon
AHA.T. Hattersley
A.T. Hattersley

9 January 2015 in BMJ Open
Verified
Journal Article
Open access
ACAmelia O Clive
Amelia O Clive
PWPaula Wilson
Paula Wilson
HTHazel Taylor
Hazel Taylor
AMAnna J Morley
Anna J Morley
EWEmma de Winton
Emma de Winton
NMNick Maskell
Nick Maskell
Introduction: Patients with malignant pleural mesothelioma (MPM) may develop painful ‘procedure tract metastasis’ (PTM) at the site of previous pleural interventions. Prophylactic radiotherapy has been used to minimise this complication; however, three small randomised trials have shown conflicting results regarding its effectiveness. The surgical and large bore procedures in malignant pleural mesothelioma and radiotherapy trial (SMART Trial) is a suitably powered, multicentre, randomised controlled trial, designed to evaluate the efficacy of prophylactic radiotherapy within 42 days of pleural instrumentation in preventing the development of PTM in MPM. Methods and analysis: 203 patients with a histocytologically proven diagnosis of MPM, who have undergone a large bore pleural intervention (thoracic surgery, large bore chest drain, indwelling pleural catheter or local anaesthetic thoracoscopy) in the previous 35 days, will be recruited from UK hospitals. Patients will be randomised (1:1) to receive immediate radiotherapy (21 Gy in 3 fractions over 3 working days within 42 days of the pleural intervention) or deferred radiotherapy (21 Gy in 3 fractions over 3 working days given if a PTM develops). Patients will be followed up for 12 months. The primary outcome measure is the rate of PTM until death or 12 months (whichever is sooner), as defined by the presence of a clinically palpable nodule of at least 1 cm diameter felt within 7 cm of the margins of the procedure site as confirmed by two assessors. Secondary outcome measures include chest pain, quality of life, analgaesic requirements, healthcare utilisation and safety (including radiotherapy toxicity). Ethics and dissemination: The trial has received ethical approval from the Southampton B Research Ethics Committee (11/SC/0408). There is a Trial Steering Committee, including independent members and a patient and public representative. The trial results will be published in a peer-reviewed journal and presented at international conferences. Trial registration number: ISRCTN72767336.